Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients: Letters: Original Observations

Diabetic Medicine

Volumn 26, Issue 2, 2009, Pages 187-188

  Narita, T ^a   Katsuura, Y ^a   Sato, T ^a   Hosoba, M ^a   Fujita, H ^a   Morii, T ^a   Yamada, Y ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MIGLITOL; PIOGLITAZONE;

DIET THERAPY; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INGESTION; INSULIN BLOOD LEVEL; JAPAN; LETTER; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS;

1-DEOXYNOJIRIMYCIN; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DIETARY FATS; DIETARY PROTEINS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; POSTPRANDIAL PERIOD;

EID: 60049089801     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02651.x     Document Type: Letter

References (7)

1. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 2006 55 : S86 S91.
2. Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W et al. α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med 2005 22 : 470 476.
3. DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly Type 2 diabetic subjects. Diabetes Res Clin Pract 2002 56 : 101 106.
4. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese Type 2 diabetics. Diabetes Obes Metab 2002 4 : 329 335.
5. Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in Type 2 diabetes mellitus. Drugs 2000 59 : 521 549.
6. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996 38 : 916 919.
7. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with Type 2 diabetes. J Clin Endocrinol Metab 2006 91 : 4612 4619.